System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 40507271 DOI: 10.3390/cancers17111790

Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations.

Cancers (Basel) 17(11)

Authors: Fedor Moiseenko, Marko Radulovic, Nadezhda Tsvetkova, Vera Chernobrivceva, Albina Gabina, Any Oganesian, Maria Makarkina, Ekaterina Elsakova, Maria Krasavina, Daria Barsova, Elizaveta Artemeva, Valeria Khenshtein, Natalia Levchenko, Viacheslav Chubenko, Vitaliy Egorenkov, Nikita Volkov, Alexei Bogdanov, Vladimir Moiseyenko

Affiliations

  • N.P Napalkov Saint Petersburg Clinical Research and Practical Centre for Specialized Types of Medical Care (Oncological), Leningradskaya Str. 68A, 197758 Saint Petersburg, Russia.
  • N.N. Petrov National Medical Research Center of Oncology, Ministry of Public Health of the Russian Federation, Leningradskaya Str. 68, 197758 Saint Petersburg, Russia.
  • Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.
  • N.P Napalkov Saint Petersburg Clinical Research and Practical Centre for Specialized Types of Medical Care (Oncological), Leningradskaya Str. 68A, 197758 Saint Petersburg, Russia. N.N. Petrov National Medical Research Center of Oncology, Ministry of Public Health of the Russian Federation, Leningradskaya Str. 68, 197758 Saint Petersburg, Russia.
  • N.P Napalkov Saint Petersburg Clinical Research and Practical Centre for Specialized Types of Medical Care (Oncological), Leningradskaya Str. 68A, 197758 Saint Petersburg, Russia. Department of Oncology, Pediatric Oncology and Radiation Therapy, St.-Petersburg State Pediatric Medical University, St. Lithuanian 2, 194100 Saint Petersburg, Russia.

Abstract

Background/Objectives: Checkpoint inhibitors (ICIs) are key therapies for NSCLC, but current selection criteria, such as excluding mutation carriers and assessing PD-L1, lack sensitivity. As a result, many patients receive costly treatments with limited benefit. Therefore, this study aimed to predict which NSCLC patients would achieve durable survival (≥24 months) with immunotherapy. Methods: A comprehensive ensemble radiomics approach was applied to pretreatment CT scans to prognosticate overall survival (OS) and predict progression-free survival (PFS) in a cohort of 220 consecutive patients with inoperable NSCLC treated with first-line ICIs (pembrolizumab or atezolizumab, nivolumab or prolgolimab) as monotherapy or in combination. The radiomics pipeline evaluated four normalization methods (none, min-max, Z-score, mean), four feature selection techniques (ANOVA, RFE, Kruskal-Wallis, Relief), and ten classifiers (e.g., SVM, random forest). Using two to eight radiomics features, 1680 models were built in the Feature Explorer (FAE) Python package. Results: Three feature sets were evaluated: clinicopathological (CP) only, radiomics only, and a combined set, using 6- and 12-month PFS and 24-month OS endpoints. The top 15 models were ensembled by averaging their probability scores. The best performance was achieved at 24-month OS with the combined CP and radiomics ensemble (AUC = 0.863, accuracy = 85%), followed by radiomics-only (AUC = 0.796, accuracy = 82%) and CP-only (AUC = 0.671, accuracy = 76%). Predictive performance was lower for 6-month (AUC = 0.719) and 12-month PFS (AUC = 0.739) endpoints. Conclusions: Our radiomics pipeline improved selection of NSCLC patients for immunotherapy and could spare non-responders unnecessary toxicity while enhancing cost-effectiveness.

MeSH

Carcinoma, Non-Small-Cell Lung, Immunotherapy, Machine Learning, Therapeutics, Mutation, Prognosis